FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
FDA Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
Hosted on MSN34m
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
CNN14d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Chronic kidney disease is a common complication for people ... The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set ...
Forbes14d
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest Approval
The FDA said Ozempic can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney ...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
GLP-1 medications show promise in slowing kidney disease progression
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
The Baltimore Sun13d
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death
The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with ...
Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally
Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...
McKnight's Long-Term Care News13d
FDA expands Ozempic to treat kidney disease in people with diabetes
The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...